OTC Pharmaceuticals in Russia
| Publication Date | January 2008 |
|---|---|
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 34 |
| ISBN Number | not applicable |
| Product Code | DAT02662 |
Summary
Datamonitor's OTC Pharmaceuticals in Russia industry profile is an essential resource for top-level data and analysis covering the otc pharmaceuticals industry. It includes detailed data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.
Scope
- Contains an executive summary and data on value, volume and/or segmentation
- Provides textual analysis of the industry's recent performance and future prospects
- Incorporates in-depth five forces competitive environment analysis and scorecards
- Includes a five-year forecast of the industry
- The leading companies are profiled with supporting key financial metrics
- Supported by the key macroeconomic and demographic data affecting the market
Highlights
- Detailed information is included on market size, measured by both value and volume
- Five forces scorecards provide an accessible yet in depth view of the market's competitive landscape
- Market shares are covered by manufacturer and/or brand
- Also features market breakdown by distribution channel
Why you should buy this report
- Spot future trends and developments
- Inform your business decisions
- Add weight to presentations and marketing materials
- Save time carrying out entry-level research
Market Definition
The OTC pharmaceuticals market values the total sales of analgesics, cough and cold preparations, indegestion preparations, topical OTC medicines, vitamins and minerals and other OTC healthcare products (anti-smoking aids, eye & ear drops, motion sickness medication, rectal medication and sleeping aids) at retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2006 annual average exchange rates.
Europe comprises Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Russia, Spain, Sweden and the UK.
Content
- Executive Summary
- Chapter 1 Market Overview
- 1.1 Market Definition
- 1.2 Research Highlights
- 1.3 Market Analysis
- Chapter 2 Market Value
- Chapter 3 Market Segmentation I
- Chapter 4 Market Segmentation Ii
- Chapter 5 Market Share
- Chapter 6 Five Forces Analysis
- 6.1 Summary
- 6.2 Buyer Power
- 6.3 Supplier Power
- 6.4 New Entrants
- 6.5 Substitutes
- 6.6 Rivalry
- Chapter 7 Leading Companies
- 7.1 Ranbaxy Laboratories Limited
- 7.2 Zentiva Nv
- 7.3 Pfizer Inc
- Chapter 8 Distribution
- Chapter 9 Market Forecasts
- 9.1 Market Value Forecast
- Chapter 10 Macroeconomic Indicators
- Chapter 11 Appendix
- 11.1 Methodology
- 11.2 Industry Associations
- 11.3 Related Datamonitor Research
- List Of Tables
- Table 1: Russia Otc Pharmaceuticals Market Value: $ Billion, 2003-2007
- Table 2: Russia Otc Pharmaceuticals Market Segmentation I: % Share, By Value, 2007
- Table 3: Russia Otc Pharmaceuticals Market Segmentation Ii: % Share, By Value, 2007
- Table 4: Russia Otc Pharmaceuticals Market Share: % Share, By Value, 2007
- Table 5: Key Facts: Ranbaxy Laboratories Limited
- Table 6: Key Financials: Ranbaxy Laboratories Limited
- Table 7: Key Facts: Zentiva Nv
- Table 8: Key Financials: Zentiva Nv
- Table 9: Key Facts: Pfizer Inc
- Table 10: Key Financials: Pfizer Inc
- Table 11: Russia Otc Pharmaceuticals Distribution: % Share, By Value, 2007
- Table 12: Russia Otc Pharmaceuticals Market Value Forecast: $ Billion, 2007-2012
- Table 13: Russia Size Of Population (Million) , 2003-2007
- Table 14: Russia Gdp (Constant 2000 Prices, $ Billion), 2003-2007
- Table 15: Russia Inflation, 2003-2007
- Table 16: Russia Exchange Rate, 2003
About this Product
Delivery Details
PDF:Delivered by email usually within 4 to 8 UK business hours.
Related Products
Recently Viewed Products
- AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment >>
- Sanofi-Aventis and Pfizer Stop Development of a Class of Anti-obesity drugs >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Have your Healthcare Costs Reduced with Personalized Healthcare >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















